Healthcare -
Biotechnology - NASDAQ - US
$ 1.05
7.37 %
$ 63.6 M
Market Cap
-0.61
P/E
1. INTRINSIC VALUE
Balance Sheet
Acumen Pharmaceuticals, Inc.
| Current Assets | 178 M |
| Cash & Short-Term Investments | 172 M |
| Receivables | 0 |
| Other Current Assets | 6.75 M |
| Non-Current Assets | 60.7 M |
| Long-Term Investments | 0 |
| PP&E | 339 K |
| Other Non-Current Assets | 60.3 M |
| Current Liabilities | 27.6 M |
| Accounts Payable | 5.65 M |
| Short-Term Debt | 133 K |
| Other Current Liabilities | 21.8 M |
| Non-Current Liabilities | 29.6 M |
| Long-Term Debt | 28.6 M |
| Other Non-Current Liabilities | 970 K |
EFFICIENCY
Earnings Waterfall
Acumen Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 114 M |
| Operating Income | -114 M |
| Other Expenses | -11.7 M |
| Net Income | -102 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Acumen Pharmaceuticals, Inc.
| Net Income | -102 M |
| Depreciation & Amortization | 178 K |
| Capital Expenditures | -16 K |
| Stock-Based Compensation | 9.64 M |
| Change in Working Capital | 11.7 M |
| Others | 2.03 M |
| Free Cash Flow | -86.2 M |
Wall Street Analysts Price Targets
Acumen Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for ABOS of $7 , with forecasts ranging from
a
low of
$7 to a high of $7 .
ABOS Lowest Price Target
Wall Street Target
7 USD
566.67%
ABOS Average Price Target
Wall Street Target
7 USD
566.67%
ABOS Highest Price Target
Wall Street Target
7 USD
566.67%
4. DIVIDEND
ANALYSIS
ABOS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Acumen Pharmaceuticals, Inc.
Sold
0-3 MONTHS
92 K USD 5
3-6 MONTHS
167 K USD 5
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease
globenewswire.com
- 2 weeks ago
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and Chief Business Officer Jim Doherty - President and Chief Development Officer Eric Siemers - Chief Medical Officer Conference Call Participants Jason Zemansky - Bank of America Pete Stavropoulos - Cantor Fitzgerald Ting Liu - UBS Tom Shrader - BTIG Ananda Ghosh - H. C. Wainwright & Company Operator Good day and welcome to Acumen Pharma Fiscal Year 2024 Conference Call and Webcast.
seekingalpha.com
- 3 weeks ago
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
globenewswire.com
- 1 month ago
Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ: ABOS) CEO Daniel O ' Connell and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today's Marketplace host Elizabeth Hart to discuss Alzheimer's Disease.
globenewswire.com
- 1 month ago
Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting
Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug
globenewswire.com
- 1 month ago
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
NEWTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in webcast fireside chats at two upcoming investor conferences:
globenewswire.com
- 1 month ago
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET.
globenewswire.com
- 4 months ago
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q3 2024 Results Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Braun - Head of Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer, Chief Business Officer Dr. Jim Doherty - President, Chief Development Officer Dr. Eric Siemers - Chief Medical Officer. Conference Call Participants Mark Hitrik - Stifel Tom Shrader - BTIG Cameron Bozdog - BofA Securities Samantha Schaeffer - Cantor Fitzgerald Operator Hello, and welcome to Acumen Pharmaceuticals Q3 2024 Conference Call and Webcast.
seekingalpha.com
- 5 months ago
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Monday, Nov. 18, 2024, at 11:30 a.m. ET.
globenewswire.com
- 5 months ago
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference
NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the UBS Global Healthcare Conference on Wednesday, Nov. 13, 2024, at 1:15 p.m. PT (4:15 p.m. ET).
globenewswire.com
- 5 months ago
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference
NEWTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today presented updated data on a validated research-use plasma pTau217 assay to screen potential participants in the ongoing Phase 2 ALTITUDE-AD clinical trial of sabirnetug, at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference. The study found that this enrichment screening approach is resulting in a higher proportion of participants who meet the amyloid PET or CSF-based inclusion criteria compared to Acumen's Phase 1 INTERCEPT-AD trial, which did not use this approach. Furthermore, the enrichment approach is resulting in a more efficient participant selection process that reduces unnecessary amyloid PET scans or lumbar puncture (LP) procedures among people who are not eligible to continue in screening.
globenewswire.com
- 5 months ago
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference
- Presentation to focus on use of validated pTau217 assay in participant screening process for Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer's disease
globenewswire.com
- 5 months ago
8. Profile
Summary
Acumen Pharmaceuticals, Inc. ABOS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 63.6 M
Dividend Yield
0.00%
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Contact
427 Park Street, Charlottesville, VA, 22902
https://acumenpharm.com
IPO
Date
July 1, 2021
Employees
61
Officers
Dr. Grant A. Krafft Ph.D.
Co-Founder
Mr. Matt Zuga
Chief Financial Officer & Chief Business Officer
Mr. Daniel J. O'Connell M.B.A.
Chief Executive Officer & Director
Ms. Kelly Carranza
Vice President, Finance & Accounting and Corporate Controller
Ms. Alex Braun M.B.A.
Vice President & Head of Investor Relations
Mr. Derek M. Meisner Esq., J.D.
Chief Legal Officer & Corporate Secretary
Dr. Caleb E. Finch Ph.D.
Co-Founder
Mr. Russell Barton M.S.
Chief Operating Officer
Dr. James Doherty Ph.D.
President & Chief Development Officer
Dr. William L. Klein Ph.D.
Co-Founder